Measurement of neutrophil gelatinase-associated lipocalin (NGAL) in patients with non-communicable diseases: any additional benefit?

References

• Borregaard N, Cowland JB. (2006). Neutrophil gelatinase-associated lipocalin, a siderophore-binding eukaryotic protein. Biometals, 19:211–15
   PubMed Web of Science ®Google Scholar
• Clerico A, Galli C, Fortunato A, Ronco C. (2012). Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: A review of the laboratory characteristics and clinical evidences. Clin Chem Lab Med, 50:1505–17
   PubMed Web of Science ®Google Scholar
• Clifton MC, Corrent C, Strong RK. (2009). Siderocalins: Siderophore binding proteins of the innate immune system. Biometals, 22:557–64
   PubMed Web of Science ®Google Scholar
• de Geus H, Bakker J. (2011). Limits of neutrophil gelatinase–associated lipocalin at intensive care unit admission for prediction of acute kidney injury. Am J Resp Crit Care Med, 184:143
   PubMed Web of Science ®Google Scholar
• Delanaye P, Mariat C. (2013). The applicability of eGFR equations to different populations. Nat Rev Nephrol, 9:513–22
   PubMed Web of Science ®Google Scholar
• Devarajan P. (2010). Neutrophil gelatinase-associated lipocalin: A promising biomarker for human acute kidney injury. Biomarkers Med, 4:265–80
   PubMed Web of Science ®Google Scholar
• Ezenwaka CE, Jones-Lecointe A, Nwagbara E, et al. (2008). Anemia and kidney dysfunction in Caribbean type 2 diabetic patients. Cardiovasc Diabetol, 27:25
   Web of Science ®Google Scholar
• Flower DR, North AT, Attwood TK. (1993). Structure and sequence relationships in the lipocalins and related proteins. Protein Sci, 2:753–61
   PubMed Web of Science ®Google Scholar
• Gowda S, Desai PB, Kulkarni SS, et al. (2010). Markers of renal function tests. N Am J Med Sci, 2:170–3
   PubMedGoogle Scholar
• Kos I, Prkačin I. (2014). Diabetic nephropathy as a cause of chronic kidney disease. Acta Med Croatica, 68:375–81
   PubMedGoogle Scholar
• Levey AS, Stevens LA, Schmid CH, et al. (2009). CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med, 150:604–12
   PubMed Web of Science ®Google Scholar
• Malyszko J, Bachorzewska-Gajewska H, Malyszko JS, et al. (2008a). Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in hypertensive and normotensive patients with coronary artery disease. Nephrology (Carlton), 13:153–6
   PubMed Web of Science ®Google Scholar
• Malyszko J, Bachorzewska-Gajewska H, Sitniewska E, et al. (2008b). Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in non-diabetic patients with stage 2-4 chronic kidney disease. Ren Fail, 30:625–8
   PubMed Web of Science ®Google Scholar
• Malyszko J, Malyszko JS, Bachorzewska-Gajewska H, et al. (2009a). Neutrophil gelatinase-associated lipocalin is a new and sensitive marker of kidney function in chronic kidney disease patients and renal allograft recipients. Transplant Proc, 41:158–61
   PubMed Web of Science ®Google Scholar
• Malyszko J, Malyszko JS, Mysliwiec M. (2009b). Serum neutrophil gelatinase-associated lipocalin correlates with kidney function in renal allograft recipients. Clin Transplant, 23:681–6
   PubMed Web of Science ®Google Scholar
• McCullough PA, Williams FJ, Stivers DN, et al. (2012). Neutrophil gelatinase-associated lipocalin: A novel marker of contrast nephropathy risk. Am J Nephrol, 35(6):509–14
   PubMed Web of Science ®Google Scholar
• Murray CJL, Lopez AD. (1997). Alternative projections of mortality and disability by cause 1990–2020: Global burden of disease study. Lancet, 439:1498–504
   Web of Science ®Google Scholar
• Portal AJ, McPhail MJ, Bruce M, et al. (2010). Neutrophil gelatinase-associated lipocalin predicts acute kidney injury in patients undergoing liver transplantation. Liver Transpl, 16:1257–66
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Schieppati A, Ruggenenti P. (2002). Nephropathy in patients with type 2 diabetes. N Engl J Med, 346:1145–51
   PubMed Web of Science ®Google Scholar
• Republic of Trinidad and Tobago Pharmaceutical Country Profile. (2012). Published by the Ministry of Health in collaboration with the Pan American Health Organization/World Health Organization (PAHO/WHO), p. 5
   Google Scholar
• Roglic G, Unwin N. (2010). Mortality attributable to diabetes: Estimates for the year 2010. Diabetes Res Clin Pract, 87:15–9
   PubMed Web of Science ®Google Scholar
• Schmidt-Ott KM, Mori K, Li JY, et al. (2007). Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol, 18:407–13
   PubMed Web of Science ®Google Scholar
• Soyibo AK, Barton EN. (2007). Report from the Caribbean Renal Registry, 2006. West Indian Med J, 56:355–63
   PubMed Web of Science ®Google Scholar
• Soyibo AK, Barton EN. (2009). Chronic renal failure from the English-speaking Caribbean: 2007 data. West Indian Med J, 58:596–600
   PubMed Web of Science ®Google Scholar
• Soyibo AK, Roberts L, Douglas LL, et al. (2012). Renal disease in the Caribbean: The disease of the past, present and future. West Indian Med J, 61:418–21
   PubMed Web of Science ®Google Scholar
• van Deursen VM, Damman K, Voors AA, et al. (2014). Prognostic value of plasma neutrophil gelatinase-associated lipocalin for mortality in patients with heart failure. Circ Heart Fail, 7:35–42
   PubMed Web of Science ®Google Scholar
• Verbrugge FH, Dupont M, Shao Z, et al. (2013). Novel urinary biomarkers in detecting acute kidney injury, persistent renal impairment, and all-cause mortality following decongestive therapy in acute decompensated heart failure. J Card Fail, 19:621–8
   PubMed Web of Science ®Google Scholar
• Vukovich TC, Proidl S, Knobl P, Teufelsbauer H, et al. (1992). The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients. Thromb Haemost, 68:253–6
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO): Global Health Observatory (GHO) Data. (2015). Non-communicable disease mortality and morbidity. Available from: www.who.int/gno/ncd/mortality_morbidity/en/ [last accessed 28 Sept 2015]
   Google Scholar